Home > Press > NanoViricides Assigned $5 Million in FY08 Defense Authorization Bill
Abstract:
Funding Focuses R&D on Treatment of Dengue Fever
NanoViricides Assigned $5 Million in FY08 Defense Authorization Bill
WEST HAVEN, CT | Posted on June 5th, 2007
The new spending authority Defense authorization bill now making its way through Congress designates $5 million for Connecticut-based NanoViricides, Inc.'s antiviral research, according to an announcement by Senator Joeseph Lieberman.
The funding is designed to explore treatment for dengue fever, an often deadly mosquito-born disease.
"This is a disease that is dangerous for anyone, but can be particularly detrimental to deployed military units," said NanoViricides' CEO Eugene Seymour, MD, MPH. "We are developing type-specific as well as broad-spectrum nanoviricides against dengue viruses in collaboration with the Walter Reed Army Institute of Research (WRAIR). This funding will be instrumental in supporting our activities." In April, NanoViricides signed a cooperative research and development agreement (CRADA) with the Walter Reed Army Institute of Research to work on dengue fever treatments.
The first attack of dengue fever is not deadly. A second attack from a different dengue virus type can lead to dengue hemorrhagic fever (DHF). DHF has a fatality rate of about 15% in the Americas, according to the Pan American Health Organization (PAHO) statistics in 2007. It is estimated that there are over 100 million cases of dengue fever and 500,000 cases of DHF worldwide each year, according to the Centers for Disease Control and Prevention (CDC).
There is currently no vaccine or effective treatment for dengue.
"We have asked our brave men and women in the armed services to make the greatest sacrifices in service to this nation," Lieberman said in a statement announcing the defense authorizations, adding further, "Providing them with effective protections on the ground and in the air is the very least we can do."
NanoViricides thanks Senator Lieberman for his leadership as well as Senator Dodd along with other members of the Senate Armed Services Committee for their support in acknowledging the groundbreaking potential of our technologies.
There can be no assurance that this research and development effort may ever lead to the development of a nanopharmaceutical product approved for commercial resale or that, if approved, a commercial market will develop for our products.
####
About NanoViricides
NanoViricides, Inc. (Pink Sheets: NNVC) is a development stage company that is creating special purpose nanomaterials for viral therapy. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
For more information, please click here
Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200
Copyright © Business Wire 2007
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
Govt.-Legislation/Regulation/Funding/Policy
Beautiful "flowers" self-assemble in a beaker: Elaborate nanostructures blossom from a chemical reaction perfected at Harvard May 17th, 2013
Artificial Forest for Solar Water-Splitting: Berkeley Lab Researchers Report First Fully Integrated Artificial Photosynthesis Nanosystem May 17th, 2013
Moth-Inspired Nanostructures Take the Color Out of Thin Films May 17th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Grants/Awards/Scholarships/Gifts/Contests/Honors/Records
Beautiful "flowers" self-assemble in a beaker: Elaborate nanostructures blossom from a chemical reaction perfected at Harvard May 17th, 2013
Add boron for better batteries: Rice University theorists say graphene-boron mix shows promise for lithium-ion batteries May 17th, 2013
Nanotechnology Pioneer Named 'Entrepreneur of the Year': Royal Society of Chemistry honors Chad Mirkin for commercializing innovations May 10th, 2013
International Space Development Conference Highlights - Dr A.P.J. Abdul Kalam Former President of India - Winner of the 2013 Wernher von Braun Memorial Award May 8th, 2013